Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GenVec HIV vaccine well-tolerated in phase I
Safety and immune response data were presented from the first of several ongoing phase I clinical trials involving the HIV vaccine candidate at a Keystone Symposium in Alberta,
Safety and immune response data were presented from the first of several ongoing phase I clinical trials involving the HIV vaccine candidate at a Keystone Symposium in Alberta,
Over the course of 18 years, 30 children aged 18 years and younger were treated with tetrabenazine at Columbia University Medical Center for a variety of hyperkinetic movement
This phase IIb study is an international, multicenter, open label, randomized, controlled clinical trial to evaluate the safety and efficacy of treatment with CoFactor plus 5-fluorouracil (5-FU) in
The National Cancer Institute-sponsored trial was designed to evaluate Avastin (bevacizumab) plus paclitaxel chemotherapy in first-line metastatic breast cancer, with the primary endpoint being an improvement in progression-free
The follow-up study, named 16-LTF, provides clinical assessment of patients who first enrolled in the Betaseron (interferon beta-1b) pivotal trial between 1988 and 1990. The results of the
The data were presented at the 40th annual meeting of the European Association for the Study of the Liver (EASL) in Paris, France. The phase II clinical trial,
The FDA accepted EntreMed’s Panzem (2- methoxyestradiol, or 2ME2) application upon review of data from preclinical experiments and a phase I clinical study, together with in vitro data
Although this approval is good news for Merck, and for many patients, the new stroke risk indication is based on the landmark LIFE trial, which indicated that this
In June 2003, Curis established a collaboration with Genentech for the development of a set of technologies based on inhibition of the Hedgehog signaling pathway, including small molecule
In this phase IIa clinical trial, valopicitabine (NM283) in combination with pegylated interferon was evaluated in treatment-naive genotype 1 hepatitis C patients. In the trial, nine patients receiving